Traditional Chinese medicine composition for thunder-fire moxibustion for preventing and treating cardiovascular diseases

Abstract

The invention relates to a traditional Chinese medicine composition for preventing and treating cardiovascular diseases through thunder-fire moxibustion, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from radix salviae miltiorrhizae, rhizoma chuanxiong, rhizoma galangae, fructus piperis longi and rhizoma corydalis. According to the traditional Chinese medicine composition, the prescription medicine with the effects of being fragrant, pungent and capable of warming meridians and dredging collaterals is applied by selecting acupoints according to an external treatment method of thunder-fire moxibustion, the effects of fragrant warming and dredging, dispersing blood stasis and dredging collaterals can be achieved, a series of symptoms of chest stuffiness and pains caused by internal blockage of cold evil are treated, coronary artery slow blood flow is treated, angina attack is rapidly relieved, and the frequency and degree of angina are relieved; the average volume ratio of C-reactive protein and leukocyte / platelets is reduced, and the life quality of a patient is improved.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and in particular to a traditional Chinese medicine composition for thunder-fire moxibustion for preventing and treating cardiovascular diseases. Background Art

[0002] Coronary Slow Flow (CSF) is a phenomenon seen in coronary angiography where the coronary artery lumen has no obvious stenosis or obstruction, but the contrast agent filling is delayed, the elimination is retarded, and the blood flow is slowed down. It can occur in a single blood vessel or involve multiple blood vessels. Clinically, patients with CSF mostly present with symptoms suspected of coronary heart disease such as chest pain and stuffiness, and mostly onset in winter and spring seasons. Because imaging has confirmed that there is no obvious stenosis in the coronary arteries, it has been generally considered that the lesions in the CSF population are mostly benign in the past. However, recent studies have shown that it is still related to poor prognosis. CSF is even the pathological basis for acute myocardial infarction, sudden death, and other cardiovascular adverse events. Traditional Chinese medicine believes that angina pectoris related to CSF is mostly due to cold congealing and blood stasis, and is more likely to be induced in winter and spring seasons. Modern medicine treats CSF mostly by orally taking vasodilators such as nitrates, nicorandil, and diltiazem, which have certain clinical effects, but generally have a short maintenance time, and angina pectoris may still recur after drug withdrawal. At the same time, these drugs often cause some adverse reactions. Although there are many ancient prescriptions for promoting blood circulation and removing stasis, their effects mostly focus on promoting blood circulation to dredge collaterals, or promoting blood circulation to dredge collaterals, or promoting blood circulation while strengthening the healthy qi, or promoting blood circulation while supplementing qi, or treating phlegm and blood stasis simultaneously, etc. It is difficult to treat a series of syndromes of chest impediment and heart pain caused by internal blockage of cold pathogen. The classic administration route of the treatment formula for chest impediment and heart pain is oral administration, and there are also sublingual administration and spraying and other routes. There is no external application formula yet. When taking orally, in order to enhance the power of promoting menstruation and dispersing stasis, wine is often added to decoct together to enhance the dispersing property. However, decocting medicine with wine is not suitable for women, children, or those with abnormal liver function, which also limits its scope of use. Summary of the Invention

[0003] The purpose of the present invention is to provide a traditional Chinese medicine composition for thunder-fire moxibustion for preventing and treating cardiovascular diseases by overcoming the deficiencies of the prior art.

[0004] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0005] In a first aspect, the present invention provides a traditional Chinese medicine composition, comprising Salvia miltiorrhiza, Ligusticum chuanxiong, Alpinia officinarum, Piper longum, and Corydalis yanhusuo.

[0006] The Chinese medicine composition (aromatic warming powder) of the present invention innovatively uses aromatic pungent and dispersing, meridian-warming and blood-dredging prescriptions and medicines to treat a series of symptoms of chest pain and heart pain caused by internal closure of cold evil with the external treatment method of thunder and fire moxibustion. Salvia miltiorrhiza can invigorate blood circulation and nourish blood, and has the effects of promoting menstruation and relieving pain, promoting blood circulation and removing blood stasis, clearing the heart and relieving vexation. With its power of invigorating blood circulation and invigorating menstruation, it can remove blood stasis in the body to achieve the purpose of unblocking blood vessels and ushering in the new, so it is the monarch; Chuanxiong is aromatic and has a thick qi, and is good at treating various pains caused by blood stasis and qi stagnation, as well as rheumatic pain, etc.; Corydalis yanhusuo can promote qi and relieve pain, and is good at promoting qi stagnation in the blood and blood stagnation in the qi, so it is specially used to treat various pains in the whole body, and the two are the ministers; Galangal is pungent and warm, and is suitable for bloating, hiccups, heart and spleen pain, and is an adjuvant; Piper scutellaria is aromatic and warms the middle, can dispel cold evil and relieve pain, and can lead all the medicines into the chest and diaphragm, so it is the messenger.

[0007] Furthermore, the following components are included in parts by weight: 5-20 parts of salvia miltiorrhiza, 3-12 parts of chuanxiong rhizome, 3-12 parts of galangal, 1-5 parts of longan and 3-12 parts of yanhusuo.

[0008] In a specific embodiment of the present invention, the following components are included in parts by weight: 10 parts of Salvia miltiorrhiza, 6 parts of Chuanxiong, 6 parts of Alpinia officinalis, 3 parts of Piper longum and 6 parts of Corydalis yanhusuo.

[0009] In a second aspect, the present invention provides the use of the traditional Chinese medicine composition in the preparation of drugs for preventing and treating cardiovascular diseases.

[0010] Furthermore, the cardiovascular disease includes slow coronary blood flow.

[0011] In a third aspect, the present invention provides a drug for treating cardiovascular diseases, wherein the drug contains the traditional Chinese medicine composition.

[0012] Furthermore, the medicine contains pharmaceutically acceptable additives.

[0013] Furthermore, the medicine contains moxa and / or mulberry paper.

[0014] In a specific embodiment of the present invention, the drug is a moxa cone for thunder and fire moxibustion. Using acupoint application prescription, selected acupoints can play the role of aromatic warming, blood stasis and meridian dredging. Aromatic warming and dispersing thunder and fire moxibustion can quickly relieve angina attacks.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] The present invention uses aromatic, pungent, and meridian-warming and blood-dredging prescriptions and medicines, and applies them to selected acupoints using the external treatment method of thunder-fire moxibustion. It can play the role of aromatic warming and blood-dredging, blood stasis-removing and blood-dredging, treat a series of symptoms of chest pain and heart pain caused by internal cold evil, treat slow coronary blood flow, quickly relieve angina attacks, reduce the frequency and severity of angina, reduce C-reactive protein and the average white blood cell / platelet volume ratio, and improve the quality of life of patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is the medicinal powder of the aromatic-warming and meridians-promoting powder of the present invention.

[0018] Figure 2 This is the preparation process of the thunder-fire moxibustion cone of the present invention. Among them, A is mulberry paper; B is the mulberry paper with moxa floss laid flat; C is to sprinkle the medicinal powder of the aromatic-warming and meridians-promoting powder on the moxa floss; D is the thunder-fire moxibustion cone.

[0019] Figure 3 This is the treatment process of the thunder-fire moxibustion with the aromatic-warming and meridians-promoting powder of the present invention. Among them, A is to ignite the top of the plant column (thunder-fire moxibustion cone); B is to select the acupoints to be treated with thunder-fire moxibustion; C is to align the fire head with the part to be moxibusted; D is to push out the plant column when the fire burns to the mouth of the box; E is to continue to use the thunder-fire moxibustion with the aromatic-warming and meridians-promoting powder of the present invention for treatment; Specific embodiments

[0020] To better illustrate the purpose, technical solution and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments. Other materials, reagents, etc. used in the embodiments can be obtained from commercial channels without special instructions.

[0021] Embodiment 1 Composition and preparation method of the aromatic-warming and meridians-promoting powder

[0022] The aromatic-warming and meridians-promoting powder uses prescriptions with aromatic, pungent-dispersing, warming the meridians and promoting blood circulation properties, and treats a series of symptoms of chest pain caused by internal blockage of cold pathogens by the external treatment method of thunder-fire moxibustion. Salvia miltiorrhiza promotes blood circulation and nourishes blood at the same time, with the effects of dredging meridians and relieving pain, activating blood circulation to remove stasis, and clearing the heart and relieving vexation. With its power of activating blood circulation and dredging meridians, it removes the accumulated stasis in the body to achieve the purpose of unblocking blood vessels and promoting the renewal of the old, so it is the monarch drug; Ligusticum chuanxiong is aromatic and thick in qi, and is good at treating various pains caused by blood stasis and qi stagnation, as well as rheumatic arthralgia; Corydalis yanhusuo promotes qi and relieves pain, and is good at promoting qi stagnation in blood and blood stasis in qi, so it specifically treats all pains in the whole body. The two are the minister drugs; Alpinia officinarum is pungent and warm, suitable for fullness, hiccups, and heart and spleen pain, and is the assistant drug; Piper longum is aromatic and warms the middle-jiao, relieves pain due to cold pathogens, and leads all the drugs into the chest diaphragm, so it is the envoy drug.

[0023] Composition of the aromatic-warming and meridians-promoting powder (parts by weight): 10 parts of Salvia miltiorrhiza, 6 parts of Ligusticum chuanxiong, 6 parts of Alpinia officinarum, 3 parts of Piper longum, and 6 parts of Corydalis yanhusuo. Grind them into fine powder and set aside to obtain the medicinal powder of the aromatic-warming and meridians-promoting powder ( Figure 1 ).

[0024] Lay out and cut the mulberry paper to a width of 15-20 cm and a length of 20-30 cm ( Figure 2 A), lay 30 g - 40 g of moxa floss flat on the mulberry paper as the moxa floss layer ( Figure 2 B), evenly sprinkle 50 g - 70 g of the medicinal powder of the aromatic-warming and meridians-promoting powder on the moxa floss layer ( Figure 2 C), roll it into a cylindrical strip, and finally stick the paper edge with paste and fix the cylindrical strip until it is dry to obtain the thunder-fire moxibustion cone with the aromatic-warming and meridians-promoting powder ( Figure 2 D).

[0025] The aromatic warming and dispersing thunder fire moxibustion moxa cone has a length of 15 to 20 cm and a diameter of 2.5 to 3 cm; and the thickness of each moxa layer is 0.1 to 0.2 cm.

[0026] Example 2

[0027] The subjects were patients with slow coronary blood flow and worsening angina within 30 days, including 47 patients in the treatment group and 33 patients in the control group.

[0028] 1. Both the treatment group and the control group were given isosorbide mononitrate sustained-release capsules (Beijing Yimin Pharmaceutical Co., Ltd., batch number: H20073915), 40 mg, qd (once a day), orally, for 7 days.

[0029] 2. The treatment group received Isosorbide Mononitrate Sustained-Release Capsules and also received Aromatic Warming and Powder Thunder Fire Moxibustion once a day for 7 days.

[0030] Acupoints: Tanzhong, Gaohuang, Xinshu; when using, first twist open the middle of the moxibustion box, insert the spare pin into the small hole of the box to fix the plant column (moxa cone); then light the top of the plant column ( Figure 3 A), take acupuncture points ( Figure 3 B is the Gaohuang point, aim the fire head at the part to be moxibustioned ( Figure 3 C is the Gaohuang point), 2 to 3 cm away from the skin (note to keep the fire red at all times), moxibustion until the skin turns red and deep tissues become hot (be careful to avoid burns); when the fire burns to the box mouth, take out the pin, open the bottom cover and push out the plant column with your thumb ( Figure 3 D), then fix it with a pin and continue using it ( Figure 3 E).

[0031] Example 3 Evaluation of therapeutic efficacy

[0032] 1. Observation Indicators and Efficacy Evaluation Criteria

[0033] 1. TCM symptom efficacy standards

[0034] The criteria for determining the efficacy of chest pain and heart pain are formulated in accordance with the "General Rules for the Establishment and Revision of Standards for Diagnosis and Efficacy Evaluation of Traditional Chinese Medicine Diseases and Syndromes".

[0035] Markedly effective: chest pain and heart pain completely disappeared; Effective: chest pain and heart pain attacks were reduced; Ineffective: chest pain and heart pain attacks did not change.

[0036] 2. SAQ-7 Assessment

[0037] Before and after treatment, the angina pectoris conditions of the subjects in each group were evaluated using the shortened version of the Seattle Angina Questionnaire (SAQ-7). This scale includes three non-combinable dimensions: activity limitation, angina frequency, and subjective satisfaction. After regularization, the full score of each dimension is 100 points. The higher the score, the lighter the degree of angina pectoris. SAQ-7 is short and requires patients to complete the answers independently within 5 minutes.

[0038] 3. CQQC evaluation

[0039] Before and after treatment, the quality of life of the subjects in each group was evaluated using the China Questionnaire of Quality of life in patients with Cardiovascular diseases (CQQC). The full score of this scale is 154 points. The higher the score, the fewer limitations in life. Patients are required to complete the answers independently within 5 minutes.

[0040] 3. 6MWD evaluation

[0041] Before and after treatment, the exercise tolerance of the subjects in each group was evaluated using the 6-minute walk distance (6MWD). 6MWD is defined as the farthest distance that the subject tries to walk in 6 minutes. For non-consecutive tests, a distance change greater than 30 m is considered clinically significant.

[0042] 4. Detection of CRP and WMR

[0043] Before and after treatment, fasting peripheral venous blood of the subjects in each group was collected. Using latex enhanced immunoturbidimetry, a C-reactive protein (CRP) detection kit (manufacturer: Medicalsystem Biotechnology Co., Ltd., batch number: 240325102) was used to detect C-reactive protein; a fully automatic modular blood and body fluid analyzer (manufacturer: Sysmex Corporation, model: XN-10[B3]) was used for blood routine detection. According to the results, the white blood cell / mean platelet volume ratio (White blood cells / Mean platelet volume Ratio, WMR) was calculated.

[0044] II. Treatment results

[0045] 1. Comparison of traditional Chinese medicine treatment effects

[0046] Table 1 results showed that after 7 days of treatment, the total effective rate of the treatment group was 87.24% (41 / 47), and that of the control group was 72.73% (24 / 33). Comparing between groups (χ 2 test), the curative effect of traditional Chinese medicine syndromes in the treatment group was significantly better than that in the control group, and the difference was statistically significant (P < 0.05).

[0047] Comparison of curative effects of traditional Chinese medicine syndromes of angina pectoris with slow coronary blood flow in each group

[0048]

[0049] 2. Comparison of SAQ-7 scores

[0050] Table 2 results showed that before treatment, there were no statistically significant differences in the limitation of angina pectoris activities, frequency and subjective satisfaction among groups (P > 0.05), and they were comparable. After treatment, the frequency of angina pectoris in each group improved (P < 0.05); the limitation of angina pectoris activities, frequency of angina pectoris and subjective satisfaction in the treatment group improved compared with those before treatment and were better than those in the control group (P < 0.05).

[0051] Comparison of SAQ-7 scores of female patients with slow coronary blood flow angina pectoris before and after treatment in each group

[0052]

[0053] Note: ①P < 0.05, compared with before treatment; ②P < 0.05, compared with the control group.

[0054] 3. Comparison of CQQC scores

[0055] Table 3 results showed that before treatment, there were no statistically significant differences in CQQC scores among groups (P > 0.05), and they were comparable. After treatment, the CQQC score of the treatment group improved compared with that before treatment (P < 0.05), and the improvement degree was better than that of the control group (P < 0.05).

[0056] Comparison of CQQC scores of female patients with slow coronary blood flow angina pectoris before and after treatment in each group

[0057]

[0058] Note: ①P < 0.05, compared with before treatment; ②P < 0.05, compared with the control group.

[0059] 4. Comparison of 6MWD

[0060] Table 4 results showed that before treatment, there were no statistically significant differences in 6MWD among groups (P > 0.05), and they were comparable. After treatment, 6MWD in each group improved compared with that before treatment (P < 0.05), and the improvement degree was better than that of the control group (P < 0.05).

[0061] Table 4 Comparison of 6MWD in female patients with coronary slow flow angina before and after treatment in each group

[0062]

[0063] Note: ①P<0.05, compared with before treatment; ②P<0.05, compared with control group.

[0064] 5. Comparison of CRP and WMR

[0065] The results in Table 5 show that before treatment, there was no statistically significant difference in CRP and WMR between the two groups (P>0.05), indicating that the two groups were comparable. After treatment, CRP and WMR in the treatment group improved compared with those before treatment (P<0.05), and the degree of improvement in WMR was greater than that in the control group (P<0.05).

[0066] Table 5 Comparison of CRP and WMR in female patients with coronary slow flow angina before and after treatment in each group

[0067]

[0068] Note: ①P<0.05, compared with before treatment; ②P<0.05, compared with control group.

[0069] 6. Adverse reactions

[0070] No adverse reactions were observed in the treatment group of the present invention.

[0071] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A Chinese medicine composition, characterized in that It includes Salvia miltiorrhiza, Ligusticum wallichii, Alpinia officinarum, Piper longum and Corydalis yanhusuo.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, It includes the following components in parts by weight: 5-20 parts of Salvia miltiorrhiza, 3-12 parts of Ligusticum wallichii, 3-12 parts of Alpinia officinarum, 1-5 parts of Piper longum and 3-12 parts of Corydalis yanhusuo.

3. The traditional Chinese medicine composition according to claim 2, characterized in that It includes the following components in parts by weight: 10 parts of Salvia miltiorrhiza, 6 parts of Ligusticum wallichii, 6 parts of Alpinia officinarum, 3 parts of Piper longum and 6 parts of Corydalis yanhusuo.

4. Use of the traditional Chinese medicine composition according to any one of claims 1 to 3 in the preparation of a drug for preventing and treating cardiovascular diseases.

5. The use according to claim 4, characterized in that The cardiovascular diseases include coronary slow flow.

6. A drug for preventing and treating cardiovascular diseases, characterized in that, The drug contains the traditional Chinese medicine composition according to any one of claims 1 to 3.

7. The drug according to claim 6, characterized in that, The drug contains pharmaceutically acceptable additives.

8. The drug according to claim 7, characterized in that, The drug contains moxa floss and / or mulberry paper.

9. The drug according to claim 7, characterized in that, The drug is a thunder-fire moxibustion cone.

Images